Future studies of GLP-1 resistance in human subjects targeting GLP-1 signaling may reveal whether correcting dysbiosis is a potentially novel strategy for treating NAFLD/NASH. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.